Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Affordable Covid drugs kept out of reach by sluggish WTO

Analysis: EU and US pharma giants’ intellectual property rights stop poorer countries accessing vital medication – despite WTO claims of progress

The Guardian - UK

Thailand's first lot of local Covid vaccine produced

The first batch of ChulaCov19, the first messenger-RNA vaccine developed in Thailand, has been produced and is awaiting Food and Drug Administration (FDA) approval for the first two phases of human trials, a government spokesperson said on Saturday.

Bangkok Post

Researchers Want Pfizer's Therapy Studied As Evidence Suggests Benefit for Long COVID Patients: Reuters

Additional reports of patients with long COVID who were helped by Pfizer Inc's (NYSE: PFE) oral antiviral treatment Paxlovid have surfaced, providing momentum for conducting clinical trials to test the treatment,

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

U.S. FDA extends review of Pfizer and Myovant Sciences supplemental New Drug Application (sNDA) For MYFEMBREE by three months

The U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) from Pfizer Inc.

Benzinga

Mother, 36, most likely died from Covid Pfizer vaccine 11 days after dose, inquest told

Pathologist said the mother-of-two may still be alive had she not had the Covid vaccine

The Independent UK

US Drug Regulator Limits Use of J&J Covid Vaccine

The US said Thursday only adults who "have personal concerns" about mRNA vaccines, access issues or medical reasons for refusing them may now receive the Johnson & Johnson Covid shot, which has been linked to a rare but serious clotting condition. The vaccine, which was authorized as a single shot,…

Asharq Al-Awsat

Read news from The Economist, FT, and more,
with one subscription

FDA limits use of Johnson & Johnson COVID vaccine over blood clot risks, agency says

The use of Johnson and Johnson’s COVID-19 vaccine, also known as Janssen, has been limited to “certain individuals” over rare blood clot risks, the U.S. Food and Drug Administration announced Thursday, May 5.

McClatchy Washington Bureau

Mum-of-two, 36, died from rare complications of Covid jab, inquest reveals

Mrs Wooldridge was found dead in her home by her brother in June last year, after she failed to collect her five-year-old son from school

Daily Mirror

FDA restricts J&J's COVID-19 vaccine due to blood clot risk

U.S. regulators are strictly limiting who can receive Johnson & Johnson’s COVID-19 vaccine due to a rare but serious risk of blood clots

The Independent UK

FDA Berates Pfizer CEO's Suggestion To Take More Paxlovid If COVID-19 Symptoms Rebound

The FDA berates Pfizer Inc (NYSE: PFE) CEO Albert Bourla's proposed solution in cases where virus levels rebound after the first course of treatment.

Benzinga

Commentary: COVID won’t become endemic until we have a vaccine for kids under 5

Last week, Moderna became the first manufacturer to officially ask the Food and Drug Administration to approve its COVID-19 vaccine for children under 6 years old. One of three companies with authorized COVID-19 vaccines in the United States, Moderna made the request a month after saying its data showed efficacy…

Los Angeles Times

COVID-19 dashboard: Catch up fast

The latest headlines that you need to know.

Axios

FDA contradicts Pfizer’s advice on 2nd course of COVID drug

There is “no evidence” that a second course of Pfizer Inc.’s Paxlovid will help COVID-19 patients whose symptoms return after an initial course of the antiviral, a U.S. Food and Drug Administration official said a day after Pfizer executives advocated the idea.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

Pfizer opens global drug development centre on IIT-M Research Park campus

This is the company’s first such facility in Asia

Benzinga

4 Analysts Have This to Say About Pfizer

Within the last quarter, Pfizer (NYSE:PFE) has observed the following analyst ratings:

The Conversation

Will new vaccines be better at fighting coronavirus variants? 5 questions answered

The first three coronavirus vaccines earned Emergency Use Authorization more than a year ago. To date, no other vaccines have been put into use in the U.S – but that will soon change. More than 40 vaccines are undergoing clinical trials in the U.S., employing a number of different approaches…

Al Jazeera

Recombinant COVID variants: What is Omicron XE?

When large volumes of two viruses that are genetically linked circulate, there’s a risk of a new ‘hybrid’ virus forming.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Mid-Afternoon Market Update: Kymera Therapeutics Drops After Q1 Results; Belite Bio Shares Spike Higher

U.S. stocks traded slightly higher toward the end of trading on Tuesday.

The Independent UK

Pfizer hopes to submit little-kid vaccine data by early June

Pfizer now hopes to tell U.S. regulators how well its COVID-19 vaccine works in the littlest kids by early June

Benzinga

Mid-Day Market Update: Dow Jumps 100 Points; Spero Therapeutics Shares Plunge

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Tuesday.

Benzinga

Pfizer Stock Flies Higher Following Q1 Earnings Print: Here's What To Watch For Next

Pfizer, Inc (NYSE: PFE) shot up over 3% on Tuesday after printing its first-quarter earnings before the market open.

Benzinga

Mid-Morning Market Update: Markets Mixed; Dow Drops 50 Points

U.S. stocks traded mixed this morning, with the Dow Jones dropping around 50 points on Tuesday.

The Guardian - UK

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

Benzinga

Pfizer Posts Street Beating Q1 Earnings, Revises FY22 Profit Outlook

Pfizer Inc (NYSE:PFE) has reported a Q1 adjusted EPS of $1.62, up 72% Y/Y, well ahead of the consensus of $1.50. The company achieved revenues of $25.66 billion, up 77%, beating the Wall Street estimate of $23.95 billion. Its COVID-19 vaccine, Comirnaty, contributed $13.2 billion in direct sales and alliance revenues. Eliquis…

1 … 53 54 55 56

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.